Solving the degradation problem of continuous ceftazidime infusions—the Cooltaz study
Antimicrobial Agents and Chemotherapy · 01.07.2026 · 70 (7)
DOI: 10.1128/aac.01385-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.07.2026. Verfasst von Sonia L La Vita und 2 weiteren Autor:innen. Beteiligte Einrichtung: Murdoch Children's Research Institute, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Ceftazidime, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Medical Research Futures Fund.
Abstract (Originalsprache)
Ceftazidime is an effective antipseudomonal antibiotic, used commonly in cystic fibrosis. Continuous 24-hour intravenous infusion allows children to receive daily treatment at home. However, the instability of 24-h ceftazidime infusions and production of toxic pyridine has led to recommendations not to use them. We aimed to determine a suitable target temperature to limit degradation of ceftazidime in 24-h infusions and assess effectiveness of simple temperature control. For in vitro experiments, infusers with 6g ceftazidime in 0.9% saline were incubated at 4ºC, 25ºC and 33ºC and sampled over 24h to measure ceftazidime and pyridine concentrations using high-performance liquid chromatography. For carried infuser experiments, to simulate 24-h home infusions, children carried two insulated carry bags containing ceftazidime 2g, 6g or 12g infusers with zero, 1 or 2 ice-packs for 24h. Samples were analysed for ceftazidime and pyridine concentrations. Results for in vitro experiments showed that after 24h, ceftazidime remained stable (>90% original concentration) at 4ºC and 25ºC but not 33ºC (decreased to 84%). Pyridine increased over 24h at 4ºC, 25ºC and 33ºC by 50%, 550% and 1,040% respectively. For carried infuser experiments, at a controlled temperature of 17-25ºC, ceftazidime concentration remained >90% for all infusers except 12g with no ice-pack. Pyridine production in infusers with one or two ice-packs were reduced by 44-57% compared to no ice-pack. In conclusion, adding an ice-pack to a ceftazidime infuser in an insulated carry bag halves the pyridine produced. This indicates that a temperature-controlled daily 24-h continuous intravenous infusion of ceftazidime can replace the recommended twice daily 12-h infusions, allowing patients to receive ceftazidime treatment at home.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
- Department of Paediatrics, The University of Melbourne, Parkville, Australia.
- Hospital-In-The-Home Department, The Royal Children's Hospital, Melbourne, Australia.
- Infectious Diseases Department, The Royal Children's Hospital, Melbourne, Australia.
ORCID-Profile: Penelope A Bryant
Förderung
- Australian Medical Research Futures Fund
Zitieren
APA
La Vita, S. L., Liu, B., & Bryant, P. A. (2026). Solving the degradation problem of continuous ceftazidime infusions—the Cooltaz study. Antimicrobial Agents and Chemotherapy, 70(7). https://doi.org/10.1128/aac.01385-25
Vancouver
La Vita SL, Liu B, Bryant PA. Solving the degradation problem of continuous ceftazidime infusions—the Cooltaz study. Antimicrobial Agents and Chemotherapy. 2026;70(7). doi:10.1128/aac.01385-25
BibTeX
@article{LaVita2026,
author = {La Vita, Sonia L and Liu, Beverley and Bryant, Penelope A},
title = {Solving the degradation problem of continuous ceftazidime infusions—the Cooltaz study},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {7},
doi = {10.1128/aac.01385-25}
}
EUVIMED